NASDAQ:PEPG PepGen Q2 2026 Earnings Results & Report $2.62 +0.24 (+10.08%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$2.54 -0.08 (-3.17%) As of 10/9/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. PepGen beat analyst earnings expectations in its Q2 2026 results, released August 6, 2026. The company reported EPS of -$0.26 versus the -$0.2845 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateAugust 6, 2026TimeBefore Market OpensConference Call7:00 AM ET PepGen EPS ResultsActual EPS-$0.26Consensus EPS -$0.2845Beat/MissBeat by +$0.0245One Year Ago EPSN/AEPS Beat Rate7 of last 8 quartersPepGen Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsPepGen's Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, November 12, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) PepGen Q2 2026 Earnings FAQ Did PepGen beat earnings estimates for Q2 2026? PepGen (NASDAQ:PEPG) reported earnings of -$0.26 per share for Q2 2026, beating the consensus estimate of -$0.2845. The report was announced on Thursday, August 6, 2026. When is PepGen's next earnings date? PepGen's next earnings date is estimated for Wednesday, November 11, 2026. MarketBeat tracks confirmed and estimated earnings dates for PepGen on the company's earnings history page. PepGen Earnings HeadlinesPepGen (NASDAQ:PEPG) Stock Gets Downgrade from Wall Street ZenOctober 10 at 1:31 AM | americanbankingnews.comPepGen, Inc. (NASDAQ:PEPG) Receives Consensus Rating of "Moderate Buy" from AnalystsOctober 5, 2026 | americanbankingnews.comSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from collapsing — and billionaire Sam Altman is now an investor. This under-the-radar firm is drawing serious attention from those watching the energy infrastructure space closely.October 11 at 1:00 AM | Altimetry (Ad)PepGen Inc. (PEPG) Interactive Stock Chart - Yahoo FinanceSeptember 16, 2026 | finance.yahoo.comDSMB approves dose escalation in PepGen’s FREEDOM2-DM1 studyAugust 7, 2026 | msn.comPepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB ReviewAugust 6, 2026 | businesswire.comSee More PepGen Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like PepGen? Sign up for Earnings360's daily newsletter to receive timely earnings updates on PepGen and other key companies, straight to your email. Email Address About PepGenPepGen (NASDAQ:PEPG) Inc. is a clinical-stage biotechnology company developing RNA-based therapeutics for severe neuromuscular and genetic diseases. The company’s programs are designed to address conditions caused by genetic mutations by selectively modifying or restoring the production of disease-related proteins. PepGen’s technology platform, Enhanced Delivery Oligonucleotide (EDO), uses peptide-conjugated phosphorodiamidate morpholino oligomers to improve the delivery of therapeutic oligonucleotides into muscle and other tissues. The platform is intended to support treatments that can alter RNA processing, including exon skipping and other gene-regulating approaches. The company’s lead program, PGN-EDO51, is being developed for Duchenne muscular dystrophy in patients with mutations amenable to exon 51 skipping. PepGen is also advancing programs for other neuromuscular disorders, including myotonic dystrophy type 1. Founded in 2018 and headquartered in Boston, Massachusetts, PepGen’s research and development activities are focused primarily on rare genetic diseases, with CEO James McArthur among its leadership team.View PepGen ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/05 - 10/09Delta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
